Vision comparison of two multifocal contact lenses
| ISRCTN | ISRCTN50917346 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN50917346 |
| IRAS number | 283312 |
| Secondary identifying numbers | CV20-44, IRAS 283312 |
- Submission date
- 12/06/2020
- Registration date
- 15/06/2020
- Last edited
- 18/02/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Plain English summary of protocol
Background and study aims
As part of assessing the performance and acceptance of new multifocal contact lenses it is standard to compare them to other contact lenses on the market. The aim of this study is to determine the acceptance and the vision performance of the new Invigor contact lenses compared with 1-Day Acuvue® Moist contact lenses.
Who can participate?
Adults who are at least 40 years old and who have healthy eyes and are current multifocal contact lens wearers.
What does the study involve?
Each participant attends the clinic on three occasions. At the first visit after being screened and enrolled in the study, their eyes are examined and they are fitted and dispensed with one of the two study contact lenses (which lens type is used first is randomly determined like tossing a coin). The second visit takes place 1 week after the first, during that visit the contact lens which the participant wore are assessed. Then, the participant is fitted and dispensed with the other contact lens type, which they wear for 1 week. At the third and final visit, the contact lenses that have been worn are assessed and the participant is discharged from the study.
What are the possible benefits and risks of participating?
The participants will have the opportunity to try two different types of multifocal contact lenses which they may prefer to their own multifocal contact lenses and at a later date may decide to opt for these lenses. The two contact lens types are CE marked and therefore the risks are no different to them wearing their own contact lenses.
Where is the study run from?
Ocular Technology Group - International Research Clinic (UK)
When is the study starting from and how long is it expected to run for?
April 2020 to December 2020
Who is funding the study?
CooperVision Inc (USA)
Who is the main contact?
Deborah Moore
dmoore@otg.co.uk
Contact information
Public
OTG LTD
66 Buckingham Gate
London
SW1E 6AU
United Kingdom
| Phone | +44 (0)207 222 4224 |
|---|---|
| dmoore@otg.co.uk |
Study information
| Study design | Single-centre prospective randomised (testing order) double-masked cross over study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Cluster randomised trial |
| Study setting(s) | Other |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | Clinical performance and acceptance of Invigor multifocal vs 1-day Acuvue® moist multifocal contact lenses |
| Study objectives | The performance of the new Invigor contact lens is not inferior to 1-day Acuvue® moist multifocal contact lens. |
| Ethics approval(s) | Approved 19/05/2020, East of England - Cambridge Central Research Ethics Committee (Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8388; cambridgecentral.rec.hra.nhs.uk), REC ref: 20/EE/0119 |
| Health condition(s) or problem(s) studied | Presbyopia vision correction using multifocal contact lenses |
| Intervention | Multifocal contact lenses are prescribed to provide wearers with good vision satisfaction and visual performance using the manufactures prescribing routine. It is important to compare this feature for a new contact lens with established contact lenses. The study is a cross over study, the participants wear both contact lens types, the randomisation is limited to the order of testing, the randomisation process is a computer-based randomisation selection process. The participant will wear each contact lens (Invigor multifocal or 1-day Acuvue® moist multifocal contact lenses) for a week and at the end of the week visual satisfaction will be recorded using 100 point analogue scale for different vision condition eg. driving, computer use, reading. The visual performance will be measured using computerised logMAR charts at long distance, 4 metres, and near 40 cm. |
| Intervention type | Device |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure | Overall vision satisfaction recorded on a 100-point vision analogue scale at 1 week |
| Secondary outcome measures | 1. Overall visual performance measured using LogMar visual acuity at 1 week 2. Number of contact lenses needed at the dispensing visit to determine the contact lens power to use during the study |
| Overall study start date | 01/04/2020 |
| Completion date | 30/03/2021 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 150 |
| Key inclusion criteria | There are no requirements as to participant race, gender or occupation. In order to be enrolled, each participant shall meet the following criteria: 1. At least 40 years old 2. Have read and understood the Participant Information Sheet 3. Have read, signed and dated the Informed Consent 4. Best corrected visual acuity of at least 20/25 in each eye 5. Have normal eyes with the exception of the need for visual correction 6. Current multifocal contact lens wearer 7. Spectacle refraction: Distance: Sphere: -6.00D to + 4.00D Astigmatism: 0.00D to -0.75D Near Addition: Emerging Presbyopes: +0.75D to +1.25D Established Presbyopes: +1.50D & +1.75D Advanced Presbyopes: +2.00D to +2.50D 8. Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule |
| Key exclusion criteria | To be eligible as a participant, each candidate shall be free of any ocular or medical condition that may affect the results of this study. The following are specific criteria that exclude a candidate from enrolment in this study: 1. Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear 2. Use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator 3. Monocular participants (only one eye with functional vision) or participants fit with only one lens 4. Any moderate or severe ocular condition observed during the slit-lamp examination at the enrolment visit 5. History of herpetic keratitis, ocular surgery or irregular cornea 6. Known pregnancy or lactation during the study period 7. Enrolment of the investigator or his/her staff, family members of the investigator, family members of the investigator’s staff, or individuals living in the households of these individuals |
| Date of first enrolment | 01/07/2020 |
| Date of final enrolment | 30/11/2020 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
London
SW1E 6AU
United Kingdom
Sponsor information
Industry
6150 Stoneridge Mall Road
Pleasanton
CA 94588
United States of America
| Phone | +1 (0)925 251 6600 |
|---|---|
| plazon@coopervision.com | |
| Website | http://coopervision.com |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 31/12/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | The protocol and statistical analysis plan are confidential documents from the sponsor and have been reviewed by the Ethics Committee under usual confidentiality conditions. There are no specific plans for publication or dissemination of the study results. However, an abstract for submission at an ophthalmic conference and/or a peer-reviewed publication may be generated. |
| IPD sharing plan | The data-sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Basic results | 28/01/2021 | 18/02/2021 | No | No | |
| HRA research summary | 28/06/2023 | No | No |
Additional files
- ISRCTN50917346_BasicResults_28Jan2021.docx
- uploaded 18/02/2021
Editorial Notes
18/02/2021: The basic results of this trial have been uploaded as an additional file.
15/06/2020: Trial's existence confirmed by East of England - Cambridge Central Research Ethics Committee.
